Schwab US Large Cap Growth ETF vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Schwab US Large Cap Growth ETF trades at $36.7 (market cap $65.01B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.65 (market cap $2.27B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 28.6× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Schwab US Large Cap Growth ETF is trading nearer its 52-week high, SELLAS Life Sciences Group Inc. Common Stock nearer its low. Which is the better fit depends on your goals.
| SCHG | SLS | |
|---|---|---|
Market Cap | $65.01B | $2.27B |
Volume | 8,554,399 | 4,179,659 |
Sector | Sector/Thematic | Health |
52-Week High | $36.93 | $15.46 |
52-Week Low | $28.10 | $1.39 |
Typical Hold Time | 50 Days | — |
Enterprise Value | — | $2.14B |
Signals from Pluang's Aura AI — not financial advice
SCHG (Schwab U.S. Large-Cap Growth ETF) trades at $36.60, down 0.73% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains strong institutional interest despite a recent position reduction by Corient Private Wealth. Recent news highlights SCHG's low-cost advantage and growth-focused strategy, though concentration in top holdings presents both opportunity and risk.
The outlook for SCHG remains positive given its exposure to large-cap growth stocks and cost efficiency, though investors should monitor concentration risks in top holdings and broader market volatility. The ETF's historical performance suggests potential for long-term growth, but current valuation levels warrant careful assessment relative to alternatives like GARP strategies.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →